Know Cancer

or
forgot password


Phase 1
18 Years
N/A
Not Enrolling
Both
Advanced Colorectal Cancer

Thank you

Trial Information


Inclusion Criteria:



- Histologically confirmed, locally advanced, recurrent or metastatic colorectal cancer

- ECOG 0 or 1

- Measurable disease

Exclusion Criteria:

- Prior first line therapy for advanced disease

- Significant bulk of metastatic disease or rapid progression

- If prior adjuvant therapy, relapse within 6 months of a 5-FU based regimen or 12
months of an oxaliplatin based regimen

Other protocol-defined inclusion/exclusion criteria may apply

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Tumour response as assessed by CT scan and RESIST

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals

Authority:

Australia: Department of Health and Ageing Therapeutic Goods Administration

Study ID:

CSTI571BAU14

NCT ID:

NCT01271166

Start Date:

October 2007

Completion Date:

Related Keywords:

  • Advanced Colorectal Cancer
  • Colorectal,
  • Cancer
  • Colorectal Neoplasms

Name

Location